Conversations with delegates at HBI 2018 highlighted that a heavy focus on PPPs by some of the major healthcare actors in Africa is proving to be the right approach in countries where governments hold a lot of sway.
Brazilian HMOs Notre Dame Intermedica in the wealthy Rio and Sao Paulo region and Hapvida Sistema de Saude, in the poor North and North-East, have set their IPO price ranges and revealed their offering size. One is valued at nearly twice the other, why?
Chinese private equity fund Legend Holdings will continue to expand their healthcare investment despite heavy losses in dental chain giant Bybo, in which they have a stake, the company said in their 2017 financial report. “Legend Holdings plans to expand its investment in healthcare, especially in the area of new drugs development, DNA testing and […]
ClearMedi provides comprehensive cancer care across India, but has evolved in just six years. Healthcare Nova talks to managing director Shashi Baliyan to find out what his group is doing there to fill the cancer care gap with its 'shop-in-shop' model, and how it grew so fast.
South African hospital group Netcare will exit the UK market by selling its interest in BMI Healthcare, as high rents and weakening PMI continue to erode profits. We talk to a fund manager and speculate on buyers.
The race to buy Indian hospital giant Fortis Healthcare seems to have been won by TPG Capital-backed rival Manipal, but shareholders might prefer to wait for a better bid by pan-Asian group IHH Healthcare.
Mexican lab group Grupo Diagnóstico ProA is for sale, although management wants to keep a majority stake says Chief Innovation Officer, Carlos Perez Chavez. We talk to him about opportunities and look at Salud Digna.
A disappointing birth rate saw profits plunge at Harmonicare Medical Holdings, the largest private Chinese hospital group dedicated to gynaecology, obstetrics and paediatrics, despite China scrapping its single child policy. The company's 2017 FY report shows Harmonicare’s net profit dropped by 71% to RMB27.39m (US$6.8m) and diluted earnings per share also plunged by 71% to RMB36.10 (US$5.7m). EBITDA also […]
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
